within Pharmacolibrary.Drugs.ATC.A;

model A07XA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 23.4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.066,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Racecadotril is an oral enkephalinase inhibitor used primarily as an antidiarrheal agent for the symptomatic treatment of acute diarrhea in adults and children. It acts by inhibiting the breakdown of endogenous enkephalins in the gut, reducing hypersecretion of water and electrolytes. Racecadotril is approved for clinical use in many countries, especially for pediatric diarrhea, but not approved for use in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (fasted, male and female).</p><h4>References</h4><ol><li><p>Tras, B, et al., &amp; Uney, K (2022). Can diarrhea affect the pharmacokinetics of racecadotril in neonatal calves?. <i>Journal of veterinary pharmacology and therapeutics</i> 45(5) 426–431. DOI:<a href=&quot;https://doi.org/10.1111/jvp.13078&quot;>10.1111/jvp.13078</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35706330/&quot;>https://pubmed.ncbi.nlm.nih.gov/35706330</a></p></li><li><p>Matheson, AJ, &amp; Noble, S (2000). Racecadotril. <i>Drugs</i> 59(4) 829–837. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200059040-00010&quot;>10.2165/00003495-200059040-00010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10804038/&quot;>https://pubmed.ncbi.nlm.nih.gov/10804038</a></p></li><li><p>Eberlin, M, et al., &amp; Michel, MC (2012). A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. <i>Frontiers in pharmacology</i> 3 93–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2012.00093&quot;>10.3389/fphar.2012.00093</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22661949/&quot;>https://pubmed.ncbi.nlm.nih.gov/22661949</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A07XA04;
